Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 18:11:01 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Ascelia Pharma - SPARKLE is blurred

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Ascelia Pharma - SPARKLE is blurred

2023-08-09 08:15:00

The required revaluation of a certain number of patients showed a high level of variability and this intra-reader inconsistency will require a re-evaluation of all images by a new group of independent radiology readers. Ascelia plan to give a new update regarding the timelines and the financial implications by mid-September. Our updated view is a base case valuation of SEK 11 (32) and a Bull Case of SEK 28 (100), and a Bear Case of SEK 3 (9).

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/